IPO registrations (S-1, F-1) · Registrants

Juno Therapeutics, Inc.

SEC CIK
1594864 · filings on EDGAR ↗
Registration
Form S-1, first filed 2014-11-17, last 2014-12-18; 1 initial registration, 4 amendments
Outcome
Final prospectus filed 2014-12-19; declared effective 2014-12-18
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Incorporated in
DE
Business address
400 DEXTER AVENUE NORTH, SUITE 1200, Seattle, WA 98109
EIN
46-3656275
EDGAR entity type
operating
Insiders and CEO pay
Juno Therapeutics, Inc. on the corporate pages

Offering terms

Proposed price range
$21.00–$23.00 per share (S-1/A filed 2014-12-18)
Final price
$24.00 per share, above the range (424B4 filed 2014-12-19, an initial public offering)
Shares sold
11,022,917
Gross proceeds
$264,550,008 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol JUNO
Lead underwriters
Morgan Stanley (3,582,448 shares); J.P. Morgan (3,582,448 shares); Goldman Sachs (3,306,875 shares)
Syndicate
Leerink Partners (551,146)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 8

FiledFormWhat it isName as filedEDGAR
2014-11-17S-1S-1 (registration)Juno Therapeutics, Inc.0001193125-14-414077 ↗
2014-11-24S-1/AS-1/A (amendment)Juno Therapeutics, Inc.0001193125-14-423255 ↗
2014-12-09S-1/AS-1/A (amendment)Juno Therapeutics, Inc.0001193125-14-436942 ↗
2014-12-16S-1/AS-1/A (amendment)Juno Therapeutics, Inc.0001193125-14-443418 ↗
2014-12-18S-1/AS-1/A (amendment)Juno Therapeutics, Inc.0001193125-14-445989 ↗
2014-12-18S-1MEFS-1MEF (added securities)Juno Therapeutics, Inc.0001193125-14-447155 ↗
2014-12-18EFFECTEFFECT (declared effective)Juno Therapeutics, Inc.9999999995-14-003736 ↗
2014-12-19424B4424B4 (final prospectus)Juno Therapeutics, Inc.0001193125-14-447554 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2014-12-18S-1/Aregistration statement$21.00–$23.00$22.009,250,000$203,500,000Nasdaq JUNO4primary document; range, price sentence, shares headline, proceeds computed, cover names 4document ↗
2014-12-19424B4final prospectus$24.0011,022,917$264,550,008Nasdaq JUNO4primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Arch Venture Fund VII LPTenPercentOwner32014–2016
ARCH Venture Partners VII, LLCTenPercentOwner32014–2016
ARCH Venture Partners VII, L.P.TenPercentOwner32014–2016
Barron HalDirector142014–2018
Bishop Hans EdgarDirector,OfficerCEO and President; CEO & President; See Remarks182014–2018
BRATTON DOUGLAS KTenPercentOwner72014–2017
BYBEE CLINTONTenPercentOwner32014–2016
Cassidy Bernard JOfficerGeneral Counsel and Secretary; General Counsel & Secretary232014–2018
CL Alaska, L.P.TenPercentOwner52014–2017
CRANDELL KEITHTenPercentOwner32014–2016
Crestline Investors, Inc.TenPercentOwner52014–2017
Crestline Management, LPTenPercentOwner52014–2017
Crestline SI (GP), L.P.TenPercentOwner52014–2017
EVNIN ANTHONY BDirector222014–2018
Frohlich Mark WOfficerSee Remarks42014–2016
Harr SteveOfficerCFO & Head, Corp. Development; See Remarks172014–2018
Klausner RichardDirector282014–2018
NELSEN ROBERTDirector; Director,TenPercentOwner142014–2018
PIEN HOWARD HDirector142014–2018
Tessier-Lavigne MarcDirector42014–2016
Wilderotter Mary AgnesDirector52014–2018
Levitsky HyamOfficerEVP, Research & CSO; See Remarks62015–2017
Daniel Thomas ODirector32015–2018
Azelby RobertOfficerEVP & Chief Commercial Officer; See Remarks172015–2018
AGARWAL SUNILOfficerPresident of R & D62017–2018
VESSEY RUPERTDirector12017
FLATLEY JAY TDirector62017–2018
LEE ANN L.OfficerEVP, Technical Operations42017–2018
Blue Magpie CorpTenPercentOwner12018
CELGENE CORP /DE/TenPercentOwner12018
Celgene Switzerland LLCTenPercentOwner12018

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2017-10-05Juno Therapeutics, Inc.Biotechnology$31,091,407$31,091,40711
2015-07-14Juno Therapeutics, Inc.BiotechnologyIndefinite$898,495,32423
2014-08-14Juno Therapeutics, Inc.Biotechnology$133,734,641$85,499,985221
2014-05-08Juno Therapeutics, Inc.Biotechnology$97,000,000$28,423,971341

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationJuno Therapeutics, Inc.WAState business registriesname and state
Business registrationJuno Therapeutics, Inc.WAState business registriesname and state
Business registrationJuno Therapeutics, Inc.WAState business registriesname and state
Business registrationJUNO THERAPEUTICS, INCWAState business registriesname and state
Business registrationJUNO THERAPEUTICS, INC.WAState business registriesname and state
Business registrationJUNO THERAPEUTICS, INC.WAState business registriesname and state
Plan sponsorJUNO THERAPEUTICS, INC.WAForm 5500 (employee benefit plans)EIN (EXACT)
Political committeeJUNO THERAPEUTICS POLITICAL ACTION COMMITTEE (JUNOPAC) (connected to JUNO THERAPEUTICS)WACampaign finance (FEC)name and state
Form D issuerJuno Therapeutics, Inc.WAForm D private offeringsCIK (EXACT)
Lobbying clientJUNO THERAPEUTICS, INC.WAFederal lobbying (LDA)name and state
Patent assigneeJuno Therapeutics, Inc.WAPatents (USPTO)name and state
SEC filerJuno Therapeutics, Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerJuno Therapeutics, Inc.WATrademarks (USPTO)name and state
Form 5500 plan sponsorJUNO THERAPEUTICS, INC.EIN (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), WA first:

More with this interest.

In other datasets, the same topic (Health) in WA:

Interests: Biological Products, (No Diagnostic Substances) · Health